Australia's largest stock trading and investment forum Australia's #1 stock forum

KZA

0.00%

8.0¢ kazia therapeutics limited

Shifting clinical paradigms in primary and metastatic brain...

First 375 Last

Rich&Poor

1,135 Posts.

815

20/01/21

10:15

Post #: 50296837

Originally posted by needle: ↑
Priscilla will be presenting in a few hours....I just found this information.

A bit late now to try to join in for this presentation.

See if a replay is available tomorrow....words in the preview, I think are a little different from the past from Priscilla.

The success, or even positive hint from her tonight..... is just massive for this company.

"Shifting clinical paradigms in primary and metastatic brain tumors..." not bad when the KZA drug is 43% of the trial, in 800,000 annual brain mets PA around the world.

_________________________

To join a seminar, please register here.

Column 1
1 19 Jan 202112:00PM - 01:00PMPriscilla Brastianos, MD (MGH): Shifting clinical paradigms in primary and metastatic brain tumors using genomics (Physics Seminar)Goitein RoomIn this presentation, I will present our ongoing work on our genomic characterization of primary and metastatic brain tumors. We have identified novel drivers and potentially clinically actionable mutations in meningiomas, craniopharyngiomas and brain metastases. We have translated these findings to clinical trials, including novel national multicenter genomically-driven trials.

Short Bio
Originally from Vancouver, BC, Dr. Priscilla Brastianos completed her medical school and internal medicine residency at Johns Hopkins School of Medicine and fellowship training in hematology/oncology and neuro-oncology at the Dana-Farber Cancer Institute and Massachusetts General Hospital. She is now director of the Central Nervous System Metastasis Center at Massachusetts General Hospital and leads a multi-R01-funded laboratory. Dr. Brastianos’ research focuses on understanding the genomic mechanisms that drive primary and metastatic brain tumors. She has lead studies which have identified novel therapeutic targets in brain tumors. She has more than 125 scientific publications and has translated her scientific findings to national multicenter trials. She also leads a multidisciplinary central nervous system metastasis clinic at Massachusetts General Hospital/Harvard Medical School. She has received a number of awards for her work including a ‘NextGen Star’ award by the American Association for Cancer Research, a Damon Runyon Clinical Investigator Award, a Breast Cancer Research Foundation Award, a Susan G. Komen Career Catalyst Award, and the American Brain Tumor Association Joel Gingras Award.
Expand
Shifting clinical paradigms in primary and metastatic brain tumors using genomics
Nice find needle, yes it was part of the MGH Physics seminar series. Priscilla Brastianos presentation was in the Goitein Room of the MGH were her research lab is situated.
It is a shame that this was listed at the end of the registration information - "There is no recording of this seminar available".

The suspense continues until the Elkin Lecture zoom webinar - Shifting Paradigms in Primary and Metastatic Brain Tumors: Unleashing the Power of Genomics to Clinical Care.

Regards.

KZA Price at posting: $1.31 Sentiment: Buy Disclosure: Held

5 Upvote

1 Great analysis

Top Stories

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

RCE

Recce's R327 found effective against E.coli during clinical trial

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

CMX

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Microcap Wrap: 5 explorers with news out today

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

There are more pages in this discussion • 417 more messages in this thread...

First 375 Last

Add KZA (ASX) to my watchlist

Shifting clinical paradigms in primary and metastatic brain...

Top Stories

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Recce's R327 found effective against E.coli during clinical trial

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Ava Risk Group expands US presence with A$0.7M Substation Deal

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Microcap Wrap: 5 explorers with news out today

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Featured News